David Happel - Jul 18, 2023 Form 4 Insider Report for Sagimet Biosciences Inc. (SGMT)

Role
President & CEO, Director
Signature
/s/ Dennis Hom, Attorney-in-Fact
Stock symbol
SGMT
Transactions as of
Jul 18, 2023
Transactions value $
$0
Form type
4
Date filed
7/20/2023, 04:15 PM
Previous filing
Jul 13, 2023
Next filing
Nov 20, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGMT Stock Option (Right to Buy) Disposed to Issuer $0 -1.01M -100% $0.00* 0 Jul 18, 2023 Common Stock 1.01M $7.15 Direct F1, F2
transaction SGMT Stock Option (Right to Buy) Award $0 +1.01M $0.00 1.01M Jul 18, 2023 Series A Common Stock 1.01M $7.15 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
F2 25% of the shares underlying this option shall vest and become exercisable on October 17, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.